• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于 COVID-19 疫苗效力衰减和增强的对数几率系统。

A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.

机构信息

Population Interventions Unit, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie Street, Carlton, Victoria 3053, Australia.

Population Interventions Unit, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie Street, Carlton, Victoria 3053, Australia.

出版信息

Vaccine. 2022 Jun 21;40(28):3821-3824. doi: 10.1016/j.vaccine.2022.05.039. Epub 2022 May 20.

DOI:10.1016/j.vaccine.2022.05.039
PMID:35643564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9119963/
Abstract

Immunity to SARS-CoV-2 following vaccination wanes over time in a non-linear fashion, making modelling of likely population impacts of COVID-19 policy options challenging. We observed that it was possible to mathematize non-linear waning of vaccine effectiveness (VE) on the percentage scale as linear waning on the log-odds scale, and developed a random effects logistic regression equation based on UK Health Security Agency data to model VE against Omicron following two and three doses of a COVID-19 vaccine. VE on the odds scale reduced by 47% per month for symptomatic infection after two vaccine doses, lessening to 35% per month for hospitalisation. Waning on the odds scale after triple dose vaccines was 35% per month for symptomatic disease and 19% for hospitalisation. This log-odds system for estimating waning and boosting of COVID-19 VE provides a simple solution that may be used to parametrize SARS-CoV-2 immunity over time parsimoniously in epidemiological models.

摘要

接种疫苗后,针对 SARS-CoV-2 的免疫力会随时间推移呈非线性下降,这使得对 COVID-19 政策选择可能对人群产生的影响进行建模具有挑战性。我们发现,针对疫苗效力 (VE) 的非线性下降,可以在对数几率标度上线性化,并且基于英国卫生安全局的数据,我们开发了一个随机效应逻辑回归方程,以针对 COVID-19 疫苗接种两剂和三剂后针对奥密克戎的 VE 进行建模。两剂疫苗接种后,针对有症状感染的 VE 在几率标度上每月下降 47%,下降到住院治疗时的每月 35%。三剂疫苗接种后,针对有症状疾病的 VE 在几率标度上每月下降 35%,针对住院治疗的 VE 每月下降 19%。这种用于估计 COVID-19 VE 衰减和增强的对数几率系统提供了一种简单的解决方案,可以在流行病学模型中节省地对 SARS-CoV-2 免疫力随时间推移进行参数化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4906/9119963/3788b3da4265/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4906/9119963/3788b3da4265/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4906/9119963/3788b3da4265/gr1_lrg.jpg

相似文献

1
A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.一种用于 COVID-19 疫苗效力衰减和增强的对数几率系统。
Vaccine. 2022 Jun 21;40(28):3821-3824. doi: 10.1016/j.vaccine.2022.05.039. Epub 2022 May 20.
2
Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.评估 SARS-CoV-2 疫苗诱导免疫的衰减:系统评价和荟萃分析。
JAMA Netw Open. 2023 May 1;6(5):e2310650. doi: 10.1001/jamanetworkopen.2023.10650.
3
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.COVID-19 疫苗对≥65 岁人群中出现症状的 SARS-CoV-2 感染、COVID-19 相关住院和死亡的有效性:基于国家登记数据链接的 2021 年 2 月至 9 月的队列研究。
PLoS One. 2022 Sep 13;17(9):e0274008. doi: 10.1371/journal.pone.0274008. eCollection 2022.
4
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.SARS-CoV-2 疫苗对感染、有症状和重症 COVID-19 的有效性:系统评价和荟萃分析。
BMC Infect Dis. 2022 May 7;22(1):439. doi: 10.1186/s12879-022-07418-y.
5
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.在奥密克戎毒株占主导期间,既往BNT162b2型新冠疫苗接种与儿童及青少年有症状的新冠病毒感染之间的关联
JAMA. 2022 Jun 14;327(22):2210-2219. doi: 10.1001/jama.2022.7493.
6
Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States.美国针对奥密克戎BA.1变体的免疫力减弱和增强作用的数学评估。
Math Biosci Eng. 2023 Jan;20(1):179-212. doi: 10.3934/mbe.2023009. Epub 2022 Sep 30.
7
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间,mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络,10 个州,2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
8
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络,10 个州,2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
9
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.在奥密克戎出现前后,芬兰老年人对严重 COVID-19 的疫苗有效性很高。
BMC Infect Dis. 2022 Nov 5;22(1):816. doi: 10.1186/s12879-022-07814-4.
10
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.马来西亚对 BNT162b2 和科兴疫苗的 COVID-19 疫苗有效性下降:一项观察性研究。
Int J Infect Dis. 2022 Jun;119:69-76. doi: 10.1016/j.ijid.2022.03.028. Epub 2022 Mar 22.

引用本文的文献

1
Measuring unequal distribution of pandemic severity across census years, variants of concern and interventions.衡量大流行严重程度在普查年份、关注变种和干预措施方面的不平等分布。
Popul Health Metr. 2023 Oct 29;21(1):17. doi: 10.1186/s12963-023-00318-6.
2
Prediction of the next major outbreak of COVID-19 in Mainland China and a vaccination strategy for it.中国大陆下一次新冠疫情大爆发的预测及其疫苗接种策略。
R Soc Open Sci. 2023 Aug 30;10(8):230655. doi: 10.1098/rsos.230655. eCollection 2023 Aug.
3
Persistence of the Omicron variant of SARS-CoV-2 in Australia: The impact of fluctuating social distancing.

本文引用的文献

1
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
2
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.疫苗预防严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染和 COVID-19 疾病有效性的持续时间:系统评价和荟萃回归的结果。
Lancet. 2022 Mar 5;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. Epub 2022 Feb 23.
3
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种在澳大利亚的持续存在:社交距离波动的影响。
PLOS Glob Public Health. 2023 Apr 17;3(4):e0001427. doi: 10.1371/journal.pgph.0001427. eCollection 2023.
4
Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination.两剂 BNT162b2 mRNA 疫苗接种后抗 RBD IgG SARS-CoV-2 抗体滴度衰减的数学建模。
Front Immunol. 2023 Jan 26;14:1097747. doi: 10.3389/fimmu.2023.1097747. eCollection 2023.
5
Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia.新冠肺炎最优政策的流行病学与经济学建模:澳大利亚维多利亚州的公共卫生和社会措施、口罩及疫苗
Lancet Reg Health West Pac. 2023 Mar;32:100675. doi: 10.1016/j.lanwpc.2022.100675. Epub 2023 Jan 20.
巴西异源科兴加辉瑞疫苗有效性。
Nat Med. 2022 Apr;28(4):838-843. doi: 10.1038/s41591-022-01701-w. Epub 2022 Feb 9.
4
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.疫苗引发针对 SARS-CoV-2 奥密克戎的高度保守的细胞免疫。
Nature. 2022 Mar;603(7901):493-496. doi: 10.1038/s41586-022-04465-y. Epub 2022 Jan 31.
5
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.新冠病毒疫苗对轻症和重症疾病的保护持续时间。
N Engl J Med. 2022 Jan 27;386(4):340-350. doi: 10.1056/NEJMoa2115481. Epub 2022 Jan 12.
6
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性:一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
7
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
9
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.辉瑞-生物科技疫苗和牛津-阿斯利康疫苗对英格兰老年人新冠病毒相关症状、住院及死亡率的有效性:检测阴性病例对照研究
BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088.
10
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.苏格兰首次大规模 COVID-19 疫苗接种和 COVID-19 住院的临时发现:一项全国性前瞻性队列研究。
Lancet. 2021 May 1;397(10285):1646-1657. doi: 10.1016/S0140-6736(21)00677-2. Epub 2021 Apr 23.